RecruitingUrothelial CarcinomaUrothelial Carcinoma RecurrentUrothelial Carcinoma Ureter

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

Eligible age

18+ yrs

Accepts

All genders

Locations

15 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.

Sponsor: UroGen Pharma Ltd.

You may qualify if…

✓ Adults \>18 years old and capable of giving informed consent.
✓ Diagnosis of UTUC.
✓ Receipt of at least 1 dose of JELMYTO after FDA approval (15 Apr 2020).

You may not qualify if…

✕ Incapable of giving informed consent (e.g., incarcerated individuals, individuals with dementia).
✕ Receipt of 1 or more doses of JELMYTO (also referred to as UGN-101 or Mitogel in clinical development) before FDA approval (on or before 15 Apr 2020).
✕ Pregnancy or lactation.
✕ Unable to comply with protocol requirements (for prospective data capture).
✕ Any medical or mental condition(s) that makes participation in the Registry inadvisable in the opinion of the Investigator (for prospective data capture).